Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $18.00 Consensus Target Price from Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been assigned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $18.00.

Several research firms recently commented on VYGR. Oppenheimer reissued an “outperform” rating and set a $18.00 price objective on shares of Voyager Therapeutics in a research note on Wednesday, May 15th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday, May 16th. Guggenheim started coverage on shares of Voyager Therapeutics in a research report on Tuesday, March 26th. They set a “buy” rating and a $22.00 target price for the company. Wedbush cut their target price on shares of Voyager Therapeutics from $10.00 to $8.00 and set a “neutral” rating for the company in a research report on Tuesday, May 14th. Finally, StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, May 13th.

Voyager Therapeutics Stock Up 0.8 %

Shares of Voyager Therapeutics stock opened at $7.86 on Tuesday. The firm has a market cap of $427.51 million, a PE ratio of -157.17 and a beta of 1.04. Voyager Therapeutics has a 12-month low of $6.06 and a 12-month high of $12.24. The company’s fifty day simple moving average is $8.25 and its two-hundred day simple moving average is $8.38.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Monday, May 13th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.24. The firm had revenue of $19.52 million for the quarter, compared to analyst estimates of $10.33 million. Voyager Therapeutics had a negative net margin of 2.56% and a negative return on equity of 1.28%. As a group, sell-side analysts expect that Voyager Therapeutics will post -1.39 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Voyager Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Barclays PLC raised its stake in shares of Voyager Therapeutics by 188.8% in the third quarter. Barclays PLC now owns 18,309 shares of the company’s stock valued at $141,000 after acquiring an additional 11,970 shares during the period. Kestra Advisory Services LLC bought a new stake in shares of Voyager Therapeutics in the 3rd quarter valued at about $980,000. Aigen Investment Management LP bought a new stake in shares of Voyager Therapeutics in the 3rd quarter valued at about $109,000. O Shaughnessy Asset Management LLC boosted its holdings in shares of Voyager Therapeutics by 131.2% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 51,690 shares of the company’s stock valued at $401,000 after buying an additional 29,331 shares in the last quarter. Finally, Armistice Capital LLC raised its position in shares of Voyager Therapeutics by 15.3% in the 3rd quarter. Armistice Capital LLC now owns 4,178,000 shares of the company’s stock valued at $32,380,000 after purchasing an additional 554,000 shares during the last quarter. Institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.